Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neuropace Inc (NPCE)

Neuropace Inc (NPCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 361,405
  • Shares Outstanding, K 26,284
  • Annual Sales, $ 65,420 K
  • Annual Income, $ -32,960 K
  • 60-Month Beta 2.08
  • Price/Sales 5.64
  • Price/Cash Flow N/A
  • Price/Book 17.05
Trade NPCE with:

Options Overview Details

View History
  • Implied Volatility 110.71% ( +2.78%)
  • Historical Volatility 66.16%
  • IV Percentile 68%
  • IV Rank 52.36%
  • IV High 135.32% on 01/24/24
  • IV Low 83.65% on 01/26/24
  • Put/Call Vol Ratio 0.67
  • Today's Volume 10
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 1,365
  • Open Int (30-Day) 654

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.38
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +21.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.10 +15.79%
on 04/03/24
15.77 -11.19%
on 04/09/24
+1.12 (+9.11%)
since 03/18/24
3-Month
12.10 +15.79%
on 04/03/24
18.15 -22.81%
on 02/20/24
+0.71 (+5.74%)
since 01/18/24
52-Week
3.80 +269.17%
on 04/26/23
18.15 -22.81%
on 02/20/24
+9.34 (+203.25%)
since 04/18/23

Most Recent Stories

More News
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.62% and 1.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TMO : 542.49 (-0.87%)
NPCE : 14.16 (+2.98%)
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

NeuroPace, Inc . (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the first patient with Lennox-Gastaut Syndrome...

NPCE : 14.16 (+2.98%)
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RXST : 52.30 (-1.00%)
NPCE : 14.16 (+2.98%)
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates

Alphatec (ATEC) delivered earnings and revenue surprises of -9.38% and 3.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ATEC : 12.41 (-0.80%)
NPCE : 14.16 (+2.98%)
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAY : 2.21 (+0.91%)
NPCE : 14.16 (+2.98%)
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

NeuroPace, Inc . (Nasdaq: NPCE), a commercial stage medical device company focused on transforming the lives of people living with epilepsy, today announced the first patient implanted in the NAUTILUS...

NPCE : 14.16 (+2.98%)
NeuroPace, Inc. (NPCE) Q2 2022 Earnings Call Transcript

NPCE earnings call for the period ending June 30, 2022.

NPCE : 14.16 (+2.98%)
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) delivered earnings and revenue surprises of 0% and 2.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MASS : 5.67 (+1.43%)
NPCE : 14.16 (+2.98%)
Abiomed (ABMD) Q1 Earnings Top Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ABMD : 381.02 (+0.06%)
NPCE : 14.16 (+2.98%)
NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022

MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on...

NPCE : 14.16 (+2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif.

See More

Key Turning Points

3rd Resistance Point 14.78
2nd Resistance Point 14.48
1st Resistance Point 14.12
Last Price 14.16
1st Support Level 13.46
2nd Support Level 13.16
3rd Support Level 12.80

See More

52-Week High 18.15
Last Price 14.16
Fibonacci 61.8% 12.67
Fibonacci 50% 10.97
Fibonacci 38.2% 9.28
52-Week Low 3.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar